Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) has initiated a registration phase three trial for peripheral T cell lymphoma (PTCL), which is enrolling patients and progressing as planned. The company has a strong cash position with $41.7 million in cash, cash equivalents, and marketable securities, providing a financial runway into 2026. Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) is advancing its lead program, Socolit, in multiple fronts, including a phase one trial for atopic dermatitis, which has shown no safety signals in the initial cohort. The company has received orphan drug designation and fast track designation from the FDA for Socolit in the treatment of relapsed T cell lymphoma. Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) is exploring a broad range of indications for its ITK inhibitors, including asthma, psoriasis, scleroderma, inflammatory bowel disease, and fibrotic diseases, supported by promising preclinical data. Corvus Pharmaceuticals Inc ( NASDAQ:CRVS ) reporte
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic SclerosisGlobeNewswire
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $8.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
CRVS
Earnings
- 11/12/24 - Miss
CRVS
Sec Filings
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- 10/23/24 - Form 8-K
- CRVS's page on the SEC website